The Magazine for Sleep Professionals
Sunday, May 24, 2026
Sleep Specialists, LLC, the manufacturer of Zzoma® positional therapy for obstructive sleep apnea (OSA), and iSleep Physicians, a leading virtual sleep specialist practice, have announced a collaboration to improve access to effective OSA treatment options for patients nationwide, offering a comfortable and potentially mask-free alternative to traditional CPAP therapy. Zzoma […]
Noctrix Health, Inc. announced that it has closed a $40M Series C financing round led by Sectoral Asset Management with participation from other new investors Angelini Ventures, ResMed, and Asahi Kasei Corporation, with strong support from insiders, including OrbiMed and Treo Ventures. This infusion of capital will propel the advancement […]
– SynAIRgy Compares AD109 to Placebo Over 6 Months in People with OSA who Are Intolerant of or Refuse Positive Airway Pressure (PAP) Therapy, the Current Standard of Care – Part of a two-study registrational Phase 3 program that also includes LunAIRo which began enrollment in September 2023 Apnimed, Inc., […]
NLS Pharmaceutics Ltd., a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system (“CNS”) disorders, announced that NLS has entered into an exclusive worldwide option agreement with Aexon Labs, Inc., a privately held U.S. company (“Aexon Labs”), […]
As part of the U.S. Food and Drug Administration’s continued commitment to protect and promote the public health, the agency is alerting patients and healthcare providers of an emerging safety issue involving Philips Respironics’ DreamStation 2 Continuous Positive Airway Pressure (CPAP) machines used for treatment of obstructive sleep apnea. The […]
By Amber Carmen Arroyo, PhD Continuous positive airway pressure (CPAP) therapy is the first line and is typically considered the gold standard treatment for obstructive sleep apnea (OSA).1 Yet, adherence to CPAP has been consistently low since CPAP’s inception, generally ranging from just 30 to 60%.2 Despite exponential growth in […]
Consistently sleeping less than five hours a night might raise the risk of developing depressive symptoms, according to a new genetic study led by UCL researchers. Historically, poor sleep has been seen as a side effect of mental ill health, but this study found that the link between sleep and […]
Jazz Pharmaceuticals plc announced that the Company and its partners will present 14 abstracts from across its sleep medicine portfolio, including two oral presentations, at the 17th annual World Sleep 2023 Congress, held October 20-25 in Rio de Janeiro, Brazil. The oral presentations include findings from the real-world TENOR study, […]
Kingman Strohl, MD Obstructive sleep apnea (OSA) is effectively managed by positive airway pressure (PAP) applied to the nose and/or mouth. The principle of PAP is to inflate the critical region of closure in the upper airway, usually at the base of the tongue or the uvula. The effective property […]
Jazz Pharmaceuticals plc announced that six abstracts presenting data from across its sleep medicine portfolio were featured at the 36th annual Psych Congress, held September 6-10, 2023. One of the accepted abstracts provided a comprehensive review of clinical data that assessed the impact of oxybate on sleep quality, sleep architecture and […]
